PrimeInvestor - Articles and Reports

Prime fund recommendation - A fund to play the small cap pick up
Categories
Vidya Bala

Prime Fund recommendation: A fund to play the small cap pick up

Mid and small-cap funds form a part of a long-term portfolio to boost overall portfolio returns. But there are times when these market-cap segments underperform for various reasons. The small-cap index spent much of nearly two years languishing behind the Nifty 50. This is now changing, serving up a good opportunity to focus on the small-cap segment.

Read More
Prime stock recommendation - moving this small finance bank to a HOLD
Stocks
N V Chandrachoodamani

Prime Stock recommendation: Moving this small finance bank to a HOLD

With a return of over 50%, one of our stock recommendations – on a small finance bank – may now provide less entry opportunity for new investors even as existing investors can continue to hold it. Read to know what drove this small finance bank’s stock to current valuations and what prospects it still holds.

Premium article available only to subscribers.

Read More
6 investment styles – which one suits you?
Stocks
Aarati Krishnan

6 investment styles – which one suits you?

Apart from the fund manager’s skill, a hidden factor that explains such return differences is the investment styles in which each fund is managed. Right now, many of the funds that have managed to top the charts with a 16% return are value-style funds, while the laggards are growth-oriented ones. 

Read More
SEBI sees through AMCs’ games - How the new MF proposals will impact you
Mutual funds & ETFs
Vidya Bala

SEBI sees through AMCs’ games –  How the new MF proposals will impact you

Last week, we made a quiet note about SEBI’s consultation paper on mutual funds in the PrimeInvestor Community. A consultation paper solicits opinion from the public on proposals mooted by the regulator, along with rationale for such proposals. Do note that these are proposals and have not been implemented.

Read More
Critical Illness Plan Review - Tata AIG Criti -MediCare
Insurance
Pavithra Jaivant

Critical Illness plan review: Tata AIG Criti-MediCare Insurance

We at PrimeInvestor, recommend reinforcing your insurance arsenal with a critical illness cover in addition to a hospitalization plan in order to secure your finances against medical emergencies. We have covered what you should look for when shopping for a critical illness cover in our earlier article titled ‘What to look for in a critical illness health plan’. We have also shortlisted a few critical illness covers in the market based on these criteria and reviewed them in detail.
The plans we have reviewed so far are:
Activ Secure Critical Illness Plan by Aditya Birla Health Insurance,
Criti Care policy by Bajaj Alianz General Insurance,
IFFCO Tokio’s Critical Illness Benefit Policy and
Star Critical Illness Multipay Insurance Policy.
Here, we add to this list with our review of Tata AIG’s Criti-MediCare Insurance.

Read More
NFO Review - HDFC Defence Fund
Mutual funds & ETFs
Bhavana Acharya

NFO Review: HDFC Defence Fund

If there’s one NFO that’s trying to be a hop out of the regular, it is the HDFC Defence Fund. And with good reason – the defence space has been garnering increasing attention in stock markets with defence plays rallying. This open-ended thematic fund opens for subscription today.

HDFC Defence will be the only fund on the defence theme, making it differentiated from other sector offerings. There’s also no denying the scope in the defence sector, especially after key changes in defence capex spending which focuses on indigenous procurement. So, can this NFO make a good portfolio addition?

Read More
FMCG sector: At the crossroads
Markets
N V Chandrachoodamani

FMCG sector: At the crossroads

Around this time last year, we had analysed the FMCG sector’s March 2022 quarter earnings. At the time, the sector was grappling with twin headwinds of a demand slump and rising input costs. Valuations were still expensive. Most FMCG players have declared their results for the March 2023 quarter.

Read More
Technical Outlook - fresh targets for the Nifty 50
Premium
B Krishnakumar

Technical outlook: Fresh targets for the Nifty 50

A lot has happened since our previous market update, when we discussed if the worst was over for the Nifty 50. In that update, we had mentioned that the level of 17,850 on the upside and 16,900 on the lower end are the key markers to focus on. It was also highlighted that a breakout past 17,850 could pave the way for a rally to the 18,350-18,400 zone.
The Nifty 50 index has managed the latter, breaking above 17,850 and reaching the target zone of 18,350-18,400. The question now is what is in store for the Nifty 50 index. We will look at the short-term perspective here, to address this question.

Read More
The many facets of front-running and insider trading
Markets
R Balakrishnan

The many facets of front-running and insider trading 

SEBI (Securities Exchange Board of India) has levelled charges of front-running against two big institutions that may Indians are invested with – LIC and Axis Mutual Fund. Front running and its close cousin – insider trading – were quite widely prevalent in the days of yore, before SEBI drafted elaborate regulations to keep such practices at bay. But what do today’s investors need to know about these malpractices? Here’s an explainer.

Read More
Prime fund recommendation - a beaten down sector to pick up now
Mutual funds & ETFs
Vidya Bala

Prime Fund Recommendation: A beaten-down sector to pick up now

Getting into a sector when the going is rough can pay off as kinks get ironed out and prospects look up. The complexity of this sector, along with other factors, has led to steep underperformance against the Nifty 50. But with more clarity now emerging on sustainable growth from here as well as a shift in the contours of the sector, this may be an opportune time to build up exposure to this beaten-down sector.

Read More
Prime stock recommendation - an R&D focused company in the API space
Stocks
N V Chandrachoodamani

Prime Stock Recommendation: An R&D focused company in the API space

It has been a rough ride for the Indian API industry in the past 2 years. A combination of factors including price erosion in US generics, destocking, demand fluctuation, elevated raw material costs and freight costs have hit the margins of many API plays including market favourites such as Divi’s, Laurus and Aarti Drugs. Their growth has also remained at low single digits in this period.
Still, if a company has managed to remain resilient in this period and yet corrected to valuations that make it attractive, it deserves to be noticed.

Premium article available only to subscribers.

Read More
Login to your account
OR

Become a PrimeInvestor!

Get access to fresh stocks and mutual funds recommendations.

or